Capital Raise

Arrowhead Pharmaceuticals successfully raised $625 million through convertible notes and common stock offerings. This substantial capital infusion will fund pipeline development, operations, and potential product launches. The offerings include 0.00% convertible senior notes due 2032 and common stock, with underwriters having options to purchase additional securities. The company also utilized capped call transactions to mitigate potential dilution from note conversions. Proceeds will support R&D, clinical trials, and general corporate purposes.

Globavend Holdings has priced a registered direct offering to raise approximately $1.4 million, intended for working capital and general corporate purposes. Despite the modest sum, the company’s stock fell over 29% following the announcement, reflecting investor sensitivity to equity raises and potential dilution. This trend echoes past negative reactions to previous financing activities. Globavend, an e-commerce logistics provider, aims to leverage this capital to navigate market conditions and pursue strategic opportunities, though investor confidence remains a key factor for future success.

PennyMac Mortgage Investment Trust is raising $75 million through an offering of 8.500% Exchangeable Senior Notes due 2029. These notes are guaranteed by the parent company and are exchangeable into PMT common shares at a premium. Proceeds will fund strategic initiatives, including repaying debt and general corporate purposes, bolstering the company’s balance sheet in a dynamic market.

ITT Inc. announced a public offering of 7 million shares at $167 each, with a 30‑day option for an additional 1.05 million shares, expecting net proceeds of about $1.14 billion. Proceeds will largely fund the planned acquisition of SPX FLOW, Inc., with surplus allocated to general corporate purposes, debt reduction, and strategic investments. Lead underwriters include Goldman Sachs and UBS, supported by multiple other banks. The offering, filed under ITT’s automatic shelf registration, reflects investor confidence in the company’s growth and the strategic synergy of the SPX FLOW acquisition.

Nevada Sunrise (NVSGF) closed a $650,000 private placement, issuing 13,000,000 units at $0.05 each, comprised of a share and a warrant. Due to investor demand, the offering was upsized from $600,000. Net proceeds will fund Nevada exploration, property investigations, and working capital. Securities are subject to a hold until March 7, 2026. Canaccord Genuity received cash and finder’s warrants. The offering awaits TSX Venture Exchange acceptance and is not registered in the U.S.

Grid Metals Corp. (TSXV:GRDM)(OTCQB:MSMGF) plans a C$4.03M non-brokered private placement for exploration, especially at the Falcon West cesium project. The financing involves two tranches of common and flow-through shares. Funds will also support Bird River Belt targets and general corporate purposes. A strategic investor may gain governance rights, including a board nomination. Notably, Manitoba purchasers of flow-through shares are eligible for a 30% exploration tax credit. The offerings are subject to regulatory approvals.

Sidus Space (SIDU) announced a public offering of 9.8 million Class A common shares at $1.00 per share, expecting gross proceeds of $9.8 million. The offering is set to close on September 16, 2025, with ThinkEquity as the sole placement agent. Net proceeds will go towards working capital and general corporate expenses. This capital raise aims to support Sidus Space’s operations and strategic investments amid rising competition in the space technology sector. The offering is based on a shelf registration statement filed with the SEC.

On September 3, 2025, Customers Bancorp (CUBI) announced the pricing of a public offering of 2,189,781 shares of voting common stock at $68.50 per share, expected to generate $150 million. Underwriters have an option to purchase additional shares. Net proceeds will be used for general corporate purposes, including organic growth, debt refinancing, share repurchases, preferred stock redemption, capital investments, and potential acquisitions. The offering is expected to close around September 5, 2025. This move strengthens the bank’s balance sheet amid a complex economic environment.

Milestone Pharmaceuticals announced an underwritten public offering of common shares with Series A and Series B warrants, plus pre-funded warrants for certain investors. Proceeds will primarily fund the clinical development and U.S. commercial launch of its PSVT treatment candidate, etripamil, while covering working capital. TD Cowen, Piper Sandler, and Wells Fargo Securities are joint bookrunners, with H.C. Wainwright as lead manager. This financing supports Milestone’s transition toward commercialization, though it may dilute existing shareholders.

Civista Bancshares (NASDAQ: CIVB) priced an offering of 3.29 million common shares at $21.25 each, aiming to raise ~$70 million. With an underwriters’ option, proceeds could reach $80.5 million. The capital, expected to close July 14, will fund organic growth and potential acquisitions in Midwest markets. Piper Sandler leads the transaction under Civista’s existing SEC shelf registration.